Literature DB >> 9845872

Clonidine use and abuse among methadone program applicants and patients.

M Beuger1, A Tommasello, R Schwartz, M Clinton.   

Abstract

Forty-eight consecutive applicants and 30 known clonidine-abusing methadone patients at three methadone treatment programs were surveyed regarding their use of clonidine. Two distinct patterns of clonidine use emerged. Of 22 applicants who took clonidine illicitly, 15 used it primarily to decrease opioid withdrawal, as well as for its sedating effect. Applicants mostly obtained it from physicians, used an average dose of 0.37 mg at a time, and about one third believed clonidine to be addictive. In contrast, clonidine-using patients took clonidine primarily for its psychoactive effects, including the interaction with methadone, in addition to decreasing opioid withdrawal. Patients obtained clonidine frequently on the street and from family or friends, but less from physicians. The average reported dose for patients was 0.6 mg. The vast majority of these patients felt clonidine was addictive. Our findings, when coupled with the risk inherent in clonidine overdose, suggest that further research into the identification and treatment of clonidine abuse among methadone patients is warranted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9845872     DOI: 10.1016/s0740-5472(97)00309-7

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  7 in total

1.  Effects of yohimbine on the antinociceptive and place conditioning effects of opioid agonists in rodents.

Authors:  L Morales; C Perez-Garcia; L F Alguacil
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Clonidine abuse among opiate addicts.

Authors:  S J Dennison
Journal:  Psychiatr Q       Date:  2001

3.  Promethazine misuse among methadone maintenance patients and community-based injection drug users.

Authors:  Brad J Shapiro; Kara L Lynch; Tab Toochinda; Alexandra Lutnick; Helen Y Cheng; Alex H Kral
Journal:  J Addict Med       Date:  2013 Mar-Apr       Impact factor: 3.702

4.  Changes in c-fos expression in the rat heart during morphine withdrawal. Involvement of alpha2-adrenoceptors.

Authors:  Ana González-Cuello; M Victoria Milanés; Manuel Aviles; M Luisa Laorden
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-13       Impact factor: 3.000

5.  Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment.

Authors:  William J Kowalczyk; Landhing M Moran; Jeremiah W Bertz; Karran A Phillips; Udi E Ghitza; Massoud Vahabzadeh; Jia-Ling Lin; David H Epstein; Kenzie L Preston
Journal:  Am J Drug Alcohol Abuse       Date:  2018-04-10       Impact factor: 3.829

6.  Combined abuse of clonidine and amitriptyline in a patient on buprenorphine maintenance treatment.

Authors:  J Paul Seale; Trent Dittmer; Erika J Sigman; Holly Clemons; J Aaron Johnson
Journal:  J Addict Med       Date:  2014 Nov-Dec       Impact factor: 3.702

Review 7.  Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists.

Authors:  Jamie K Lim; Jeffrey P Bratberg; Corey S Davis; Traci C Green; Alexander Y Walley
Journal:  J Addict Med       Date:  2016 Sep-Oct       Impact factor: 3.702

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.